What do you need to know about a once-daily GLP-1 RA and what can you do to help your patients taking this T2D therapy? Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D. 

This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.

Faculty Presenters:

James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, Georgia

Jeff Unger, MD, FAAFP, FACE
Diplomate, American Board of Family Practice
Assistant Clinical Professor of Family Medicine, UC Riverside School of Medicine
Riverside, California
Director, Unger Concierge Primary Care Medical Group
Rancho Cucamonga, California

Curtis L. Triplitt, PharmD, CDCES, FADCES
Clinical Associate Professor of Medicine Division of Diabetes
University of Texas Health at San Antonio
Texas Diabetes Institute, part of the University Health System
San Antonio, Texas